A story in the Nov. 17, 2000, issue of BioWorld Today said Titan Pharmaceuticals Inc.'s cash and cash equivalents were $6.3 million as of Sept. 30. That did not take into account $73.5 million the company had in short-term investments, giving it about $120 million on hand after its recent financing.

Editor's Note: The correction already was made in BioWorld Online.